In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200

Rapid Communications in Mass Spectrometry

Volumn 27, Issue 18, 2013, Pages 2115-2126

  De Brabanter, Nik ^a   Esposito, Simone ^a   Tudela, Eva ^a   Lootens, Leen ^a   Meuleman, Philip ^b   Leroux Roels, Geert ^b   Deventer, Koen ^a   Eenoo, Peter Van ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMOLECULES; BODY FLUIDS; ELECTROSPRAY IONIZATION; ENZYMATIC HYDROLYSIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PHASE SEPARATION; PHYSIOLOGY;

HIGH RESOLUTION; IN-VITRO; IN-VITRO MODELS; IN-VIVO; ORBITRAP MASS SPECTROMETRIES; ROUTINE METHOD; SOLID-PHASE EXTRACTION; SYNTHETIC CANNABINOID; TRIPLE-QUADRUPOLE MASS SPECTROMETRY; VITRO AND IN VIVO;

METABOLITES;

EID: 84882256394     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.6673     Document Type: Article

References (33)

1. M. Yonamine, D. R. Campos, R. L. D. Moreau,. Marijuana as doping in sports. Sports Med. 2003, 33, 395.
2. European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2012: The state of the drug problem in Europe.
3. EMCDDA. Online sales of new psychoactive substances/'Legal highs':Summary of results from the 2011 multilingual snapshots, 2011. http://www.emcdda. europa.eu/attachements.cfm/att-143801-EN-SnapshotSummary.pdf.
4. EMCDDA, Europol. EMCDDA-Europol 2011 Annual Report. 2011, https://www.europol.europa.eu/sites/default/files/publications/ emcdda-europol-annual-report-2011-2012-final.pdf
5. S. Hudson, J. Ramsey,. The emergence and analysis of synthetic cannabinoids. Drug Test. Anal. 2011, 3, 466.
6. EMCDDA. Understanding the 'Spice' phenomenon. 2009, pp. 1-34. DOI: ISSN 1725-5767.
7. I. Vardakou, C. Pistos, C. Spiliopoulou,. Spice drugs as a new trend: Mode of action, identification and legislation. Toxicol. Lett. 2010, 197, 157.
8. V. Auwärter, S. Dresen, W. Weinmann, M. Müller, M. Pütz, N. Ferreirõs,. "Spice" and other herbal blends: harmless incense or cannabinoid designer drugs? J. Mass Spectrom. 2009, 44, 832.
9. S. Kneisel, F. Westphal, B. Moosmann, V. Brecht, P. Bisel, C. Vidal, A. Jacobsen-Bauer, W.-R. Bork, V. Auwärter,. Cannabimimetics II: Mass spectra and ATR-IR spectra of new compounds between the end of 2010 and late 2011. Tiaft Bull. 2011, 41, 29.
10. R. Kikura-Hanajiri, N. Uchiyama, M. Kawamura, Y. Goda,. Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012. Forensic Toxicol. 2013, 31, 44.
11. R. Lindigkeit, A. Boehme, I. Eiserloh, M. Luebbecke, M. Wiggermann, L. Ernst, T. Beuerle,. Spice: a never ending story? Forensic Sci. Int. 2009, 191, 58.
12. L. Ernst, H. M. Schiebel, C. Theuring, R. Lindigkeit, T. Beuerle,. Identification and characterization of JWH-122 used as new ingredient in 'Spice-like' herbal incenses. Forensic Sci. Int. 2011, 208, 31.
13. EMCDDA, Europol. EMCDDA-Europol 2009 Annual Report. 2009. https://www.europol.europa.eu/sites/default/files/publications/ emcdda-europol-annual-report-2009.pdf.
14. M. Leonhart,. Schedules of Controlled Substances: Temporary Placement of Five Synthetic Cannabinoids Into Schedule I. 2010. http://www.gpo.gov/fdsys/pkg/ FR-2010-11-24/pdf/2010-29600.pdf
15. UNODC. Synthetic cannabinoids in herbal products. 24. http://www.unodc.org/documents/scientific/Synthetic-Cannabinoids.pdf.
16. N. Uchiyama, M. Kawamura, R. Kikura-Hanajiri, Y. Goda,. Identification and quantitation of two cannabimimetic phenylacetylindoles JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles JWH-081, JWH-015, JWH-200, and JWH-073 as designer drugs in illegal products. Forensic Toxicol. 2010, 29, 25.
17. G. Merola, Z. Aturki, G. D. Orazio, R. Gottardo, T. Macchia, F. Tagliaro, S. Fanali,. Analysis of synthetic cannabinoids in herbal blends by means of nano-liquid chromatography. J. Pharm. Biomed. Anal. 2012, 71, 45.
18. S. Strano-Rossi, L. Anzillotti, E. Castrignanò, F. S. Romolo, M. Chiarotti,. Ultra high performance liquid chromatography-electrospray ionization-tandem mass spectrometry screening method for direct analysis of designer drugs, "spice" and stimulants in oral fluid. J. Chromatogr. A 2012, 1258, 37.
19. S. Dresen, S. Kneisel, W. Weinmann, R. Zimmermann, V. Auwarter,. Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantitation of synthetic cannabinoids of the aminoalkylindole type and methanandamide in serum and its application to forensic samples. J. Mass Spectrom. 2011, 46, 163.
20. S. Kneisel, V. Auwärter,. Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction. J. Mass Spectrom. 2012, 47, 825.
21. A. Wohlfarth, K. B. Scheidweiler, X. Chen, H.-F. Liu, M. A. Huestis,. Qualitative confirmation of 9 synthetic cannabinoids and 20 metabolites in human urine using LC-MS/MS and library search. Anal. Chem. 2013, 85, 3730.
22. A. Wintermeyer, I. Moller, M. Thevis, M. Jubner, J. Beike, M. A. Rothschild, K. Bender,. In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal. Bioanal. Chem. 2010, 398, 2141.
23. I. Moller, A. Wintermeyer, K. Bender, M. Jubner, A. Thomas, O. Krug, W. Schanzer, M. Thevis,. Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test. Anal. 2011, 3, 609.
24. P. Meuleman, L. Libbrecht, R. De Vos, B. de Hemptinne, K. Gevaert, J. Vandekerckhove, T. Roskams, G. Leroux-Roels,. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005, 41, 847.
25. Q. Zhang, P. Ma, R. B. Cole, G. Wang,. Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. Anal. Bioanal. Chem. 2006, 386, 1345.
26. T. G. Sobolevskii, I. S. Prasolov, G. M. Rodchenkov,. Application of mass spectrometry to the structural identification of the metabolites of the synthetic cannabinoid JWH-018 and the determination of them in human urine. J. Anal. Chem. 2011, 66, 1314.
27. N. De Brabanter, S. Esposito, L. Geldof, L. Lootens, P. Meuleman, G. Leroux-Roels, K. Deventer, P. Van Eenoo,. In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122). Forensic Toxicol. 2013, in press, doi: 10.1007/s11419-013-0179-4
28. T. Geiger, J. Cox, M. Mann,. Proteomics on an Orbitrap benchtop mass spectrometer using all-ion fragmentation. Mol Cell Proteomics 2010, 9, 2252.
29. S. Beuck, I. Moller, A. Thomas, A. Klose, N. Schlorer, W. Schanzer, M. Thevis,. Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing. Anal. Bioanal. Chem. 2011, 401, 493.
30. Q. Zhang, P. Ma, M. Iszard, R. B. Cole, W. Wang, G. Wang,. In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3- de]1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate, a cannabinoid receptor agonist. Drug Metab. Dispos. 2002, 30, 1077.
31. Q. Zhang, P. Ma, W. Wang, R. B. Cole, G. Wang,. Characterization of rat liver microsomal metabolites of AM-630, a potent cannabinoid receptor antagonist, by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. J. Mass Spectrom. 2004, 39, 672.
32. J. F. Denissen, B. A. Grabowski, M. K. Johnson, S. A. Boyd, J. T. Uchic, H. Stein, S. Cepa, P. Hill,. The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans. Drug Metab. Dispos. 1994, 22, 880.
33. L. Lootens, P. Meuleman, O. J. Pozo, P. Van Eenoo, G. Leroux-Roels, F. T. Delbeke,. uPA(+/+)-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: Methandienone as a case study. Clin. Chem. 2009, 55, 1783.